Skip to content
clinicaltrialshub.com
Clinical Trials Hub

Clinical trials, drug development and research news

Neurology

Amyloid drugs, a second look

New data reopen the debate over who benefits from anti-amyloid antibodies.

Abstract brain imaging
Photo: Unsplash contributor · Unsplash License
Contents
  1. Background
  2. Study design
  3. What it means for patients

Background

Researchers reported the results at a major congress this year1. The findings add to a growing body of evidence.

Study design

The randomised, double-blind trial enrolled patients across 20 countries.

Arm Patients 5-yr survival
Combination 314 52%
Monotherapy 316 44%

"These are the numbers we hoped to see, but they come at a cost."

What it means for patients

Experts caution that longer follow-up is needed.

  1. ClinicalTrials.gov registry entry. ↩

Sources

  1. ClinicalTrials.gov. U.S. National Library of Medicine, 2026-01-01

Medical disclaimer: For information only, not medical advice. Speak to a qualified healthcare professional about your care.

Clara Whitfield

About the author

Clara Whitfield

MSc Molecular Biology

Clara covers oncology and drug development. She previously reported on biotech for a decade.

The Briefing

Trial results that matter, every Friday.

One email. The week's readouts, approvals and research, explained without hype.

Related reading